Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 clinical study for cancer interception in people living with LS.

Next Previous
Trial Profile

A Phase 2/3 clinical study for cancer interception in people living with LS.

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 17 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NOUS-209 (Primary)
  • Indications Hereditary nonpolyposis colorectal cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 01 Jun 2026 According to a Nouscom media release, the company stated that, together with prior alignment with the FDA and EMA on the registrational pathway, the Fast Track Designation provides both accelerated development opportunities and greater regulatory clarity as it advances NOUS-209 for Lynch Syndrome carriers.
  • 26 Mar 2025 New trial record
  • 25 Mar 2025 According to the Nouscom Media Release, Following positive Type B and C meetings with the US Food and Drug Administration (FDA), Nouscom has a clear path forward for the advancement of NOUS-209 to a potentially registration-enabling Phase 2/3 clinical study for cancer interception in people living with LS.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top